Johnson & Johnson (JNJ) plans to seek FDA approval in Q2 to use its Xarelto treatment for...


Johnson & Johnson (JNJ) plans to seek FDA approval in Q2 to use its Xarelto treatment for preventing lung clots after a large-scale Phase III study showed that the drug is as effective as and safer than standard treatments, which include Warfarin. Lung clots affect 600K Americans a year and kill up to 100K. (PR)

From other sites
Comments (2)
  • DaLatin
    , contributor
    Comments (1522) | Send Message
     
    WOW, what a novel idea. Notify the FDA.. Sometimes they just forget. Like the 550 vaginal mesh suits they'll defend soon and the FDA didn't know about them for a few years !
    26 Mar 2012, 10:12 AM Reply Like
  • Zellhoefer
    , contributor
    Comments (69) | Send Message
     
    I am 70 years old and have had two lung clots (2010) and one leg clot (2011). I take warfarin daily. Would this new Xarelto treatment affect clots in legs as well as lungs?
    28 Mar 2012, 01:05 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs